Claims for Patent: 6,551,578

Summary for Patent: 6,551,578

Title:	Modulated release particles for aerosol delivery
Abstract:	A modulated release aerosol formulation is disclosed. The formulation comprises a polysaccharide polymer having a selected medicament associated therewith, a fluid carrier for carrying and delivering the construct and a stabilizer.
Inventor(s):	Adjei; Akwete L. (Bridgewater, NJ), Zhu; Yaping (Highland Park, NJ)
Assignee:	Aeropharm Technology Incorporated (Edison, NJ)
Application Number:	09/784,556
Patent Claims:	1. A modulated release aerosol formulation, which consists essentially of, a. polymeric construct comprising a polysaccharide polymer having a selected medicament associated therewith; and b. fluid carrier for carrying and delivering said construct; and c. a stabilizer selected from the group consisting of a first stabilizer, a second stabilizer and a mixture of the foregoing stabilizers. 2. A modulated release aerosol formulation, which consists essentially of, a. selected particulate medicament; b. particles of a polysaccharide polymer having said medicament associated therewith; c. a stabilizer selected from the group consisting of a first stabilizer, a second stabilizer and a mixture of the foregoing stabilizers combined with said particles; and d. a fluid carrier for carrying and transporting said combined particles. 3. The formulation as defined in claim 1 wherein said stabilizer is a water of addition. 4. The formulation as defined in claim 1 wherein said stabilizer is said first stabilizer selected from the group consisting of (1) an amino acid selected from the group consisting of (a) a monoamino carboxylic acid of the formula, H.sub.2 N--R--COOH(I), (b) a monoamino dicarboxylic acid of the formula, H.sub.2 N--R(COOH).sub.2 (II) and (c) a diamino monocarboxylic acid of the formula (H.sub.2 N).sub.2 --R COOH (III), where R is a straight or branched alkyl radical of from 1 to 22 carbon atoms, which can be mono or poly-substituted with sulfide (--S--), oxide (--O--), hydroxyl (--OH), amide (--NH), sulfate (--SO.sub.4); aryl of the formula ##STR2## where X is hydrogen, halogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxy and nitro; and heterocyclic selected from the group consisting of thienyl, furyl, pyranyl, imidazolyl, pyrrolyl, thizolyl, oxazolyl, pyridyl, and pyrimidinyl; (2) a derivative of the amino acid selected from (a) an acid addition salt of the amino group, (b) an amide of the carboxylic acid group, (c) an ester of the carboxylic acid group obtained from aliphatic straight or branched chain alcohols of from 1 to 6 carbon atoms, (3) an ether of any of the foregoing; (4) a hydrate or semi-hydrate of any of the foregoing and (5) a mixture of the amino acid and the derivative of the amino acid. 5. The formulation as defined in claim 1 wherein said first stabilizer is an amino acid selected from the group consisting of the twenty existing amino acids. 6. The formulation as defined in claim 1 wherein said polymer is selected from the group consisting of alginic acid or a pharmaceutically acceptable salt thereof; guar gum; gum karaya; gum Benjamin, plantago ovata gum; agar; carrageenan; cellulose; galaturonic acid or a mixture of any of the foregoing polymers. 7. The formulation as defined in claim 1 wherein said medicament is a protein or peptide medicament having a molecular size ranging from about 1K Dalton to about 150 K Daltons. 8. The formulation as defined in claim 7 wherein said medicament is selected from the group consisting of an insulin, an insulin analog, an amylin, an immunodilating protein, an interleukin, an inteferon, an erythropoietan, a heparin, a thrombolytic, an antitrypsin, an antiprotease, a hormone, a growth factor, an enzyme, a nucleic acid, an immunoglobulin, an antibiotic, an antiinfective, a calcitonin, a hematopoietic factor, a vaccine, a vasoactive peptide, an antisense agent, an oligonucleotide, DNase, a cyclosporin, ribavirin or a mixture of any of the foregoing medicaments. 9. The formulation as defined in claim 7 wherein said medicament is selected from the group consisting of an insulin, an insulin analog, an amylin, glucagon, LH-RH, deltirex, leuprolide, gosorelin, nafarelin, octreotide, somatostatin, a calcitonin, parathyroid hormone, TRH, growth hormone-releasing hormone, G-CSF, G-SF, a cytokine, rhDNAse, a heparin, an oligoneucleotide, ribavirin, glucagon, acetohexamide, chiorpropamide, tolazemide, tolbutamide, glipizide, glyburide, metformin, phentolamine, tumor neurosis factor (TNF), nerve growth factor (NGF), macrophage-colony stimulating factor (M-CSF), heparinase, bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), renin, bradykinin, a bacitracin, a polymyxin, a colistin, tyrocidine, a gramicidin, a monoclonal antibody, a vaccine or a mixture of any of the foregoing medicaments. 10. The formulation as defined in claim 6 wherein said polymer is present in an amount of about 0.000001 to about 10 percent by weight of the total weight of the formulation. 11. The formulation as defined in claim 1 wherein said fluid carrier is selected from the group of propellants consisting of 1,1,1,2-tetrafluoethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof. 12. The formulation as defined in claim 1 wherein said fluid carrier is a compressed gas selected from the group consisting of air, carbon dioxide, nitrogen and a mixture of any of the foregoing compressed gases. 13. The formulation as defined in claim 1 wherein said fluid carrier is a hydrocarbon selected from the group consisting of n-butane, propane, isopentene and a mixture of any of the foregoing hydrocarbons. 14. The formulation as defined in claim 1 wherein said fluid carrier is a chlorofluorocarbon selected from the group consisting of propellant 11, propellant 12, propellant 114 and a mixture of any of the foregoing propellants. 15. The formulation as defined in claim 1 wherein said stabilizer is present in an amount ranging from about 300 parts by weight to about 2000 parts by weight to the total weight of the formulation. 16. A method of preparing a stable medicinal aerosol formulation according to claim 1, which comprises, a. combining said selected medicament with said polymer to form said polymeric construct, wherein said medicament is associated with said polymer in an amount sufficient to provide a plurality of therapeutically effective doses; b. combining said stabilizer with said construct to form a stabilizer combined construct; c. combining said construct with a fluid carrier, where said carrier is present in an amount sufficient to transport and deliver a plurality of said therapeutically effective doses, to form a mixture; and d. dispersing said mixture. 17. A method of treating in a human being or another animal a condition capable of treatment by oral or nasal inhalation, which comprises; administering a formulation according to claim 1 to said human being or animal by oral or nasal inhalation. 18. A formulation according to claim 1 in an aerosol canister equipped with a metered dose valve. 19. A metered dose inhaler containing a modulated release medicinal formulation, the formulation consisting essentially of, a. a particulate medicament in a therapeutically effective amount; b. a polysaccharide polymer with which said particulate medicament is associated to form a particulate polymeric construct; c. a fluid carrier for containing and transporting said particulate polymeric construct; and d. a suitable stabilizer selected from the group consisting of a first stabilizer, a second stabilizer and a mixture of the foregoing stabilizers present in an amount sufficient to stabilize the formulation to prevent settling, creaming or flocculation thereof for a time sufficient to allow reproducible dosing of said associated medicament after agitation of the formulation. 20. The inhaler as defined in claim 19 wherein said stabilizer is selected from the group consisting of the twenty existing amino acids, any mixture thereof and any derivative of the foregoing. 21. The inhaler as defined in claim 20 wherein said stabilizer is selected from the group consisting of (1) a di-peptide selected from a salt and an ester of oxidized and unoxidized L-cysteinylglycine, gamma-L-glutamyl-L-cysteine, N-acetyl-L-cystein-glycine; (2) a conjugated, unconjugated or polymeric form of L-Gly-L-glu and L-Val-L-Thr; (3) L-aspartyl-L-phenylamine; (4) a muramyl dipeptide; (5) a nutrient selected from L-tyrosyl-L-tyrosine, L-alanyl-L-tyrosine, L-arginyl-L-tyrosine, L-tyrosyl-L-arginin, N-Clz-L-Liu-OCH and salts and esters of the foregoing; (6) glycyl-glycine; (7) N-acetyl-L-aspartate-L-glytamate (NAAG); (8) a tripeptide selected from an oxidized and an unoxidized form of gamma-L-glutamyl-L-cysteine glycine or a muramyl tripeptide and (9) a mixture of any of the foregoing stabilizers. 22. The inhaler as defined in claim 19 wherein said stabilizer is the second stabilizer which is a water of addition. 23. The formulation as defined in claim 5 wherein said stabilizer is selected from the group consisting of (1) a di-peptide selected from a salt and an ester of oxidized and unoxidized L-cysteinylglycine, gamma-L-glutamyl-L-cysteine, N-acetyl-L-cystein-glycine; (2) a conjugated, unconjugated or polymeric form of L-Gly-L-glu and L-Val-L-Thr; (3) L-aspartyl-L-phenylamine; (4) a muramyl dipeptide; (5) a nutrient selected from L-tyrosyl-L-tyrosine, L-alanyl-L-tyrosine, L-arginyl-L-tyrosine, L-tyrosyl-L-arginin, N-Clz-L-Liu-OCH and salts and esters of the foregoing; (6) glycyl-glycine; (7) N-acetyl-L-aspartate-L-glytamate (NAAG); (8) a tripeptide selected from an oxidized and an unoxidized form of gamma-L-glutamyl-L-cysteine glycine or a muramyl tripeptide and (9) a mixture of any of the foregoing stabilizers. 24. A modulated release aerosol formulation, which consists essentially of: a. a selected particulate medicament; b. particles of a polysaccharide polymer selected from the group consisting of an alginic acid or a pharmaceutically acceptable salt thereof; guar gum; gum Karaya; gum Benjamin; plantago ovata gum; agar; carrageenan; cellulose; galaturonic acid or a mixture of any of the foregoing polymers having said medicament associated therewith; c. a fluid carrier for carrying and transporting said particles of polymer; d. a stabilizer selected from the group consisting of (1) a first stabilizer selected from the group consisting of (a) an amino acid, (b) a derivative thereof and (c) a mixture of the foregoing: and (2) a second stabilizer of a water of addition and (3) a mixture of (1) and (2); and e. cosolvent. 25. The formulation as defined in claim 24 wherein said cosolvent is ethanol.

Details for Patent 6,551,578

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2039-02-26
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008		2039-02-26
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2039-02-26